TOTUM•854: arterial hypertension

Home > TOTUM•854
Designed to reduce arterial blood pressure in people with mild to moderate elevated blood pressure, a risk factor for cardiovascular disease.

Source :
1-ESC/ESH Guidelines for the management of arterial hypertension, European Heart Journal, 2018

Arterial hypertension, the leading cardiovascular risk factor

Arterial hypertension (AHT) is the world’s most prevalent chronic disease and the leading cause of premature death. It affects all countries, whether rich or poor. Over time, AHT weakens the arteries and promotes the onset of serious diseases, predominantly heart attacks, strokes, peripheral arterial diseases and kidney failure. It is the primary cardiovascular risk factor in the world.
Sources :
-2018 ESC/ESH Guidelines for the management of arterial hypertension ;
-Prise en charge de l’hypertension artérielle de l’adulte, Recommandation de bonne pratique, HAS, 2016 www.has-sante.fr/jcms/c_2059286/fr/prise-en-charge-de-l-hypertension-arterielle-de-l-adulte

Key figures

1.13 billion people worldwide suffered from arterial hypertension in 2015. 30% to 45% of adults were hypertensive.

Source: 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension.

140/90 mmHG is the defined threshold for arterial hypertension in Europe. In the United States, the threshold value starts at 130/80 mmHg.

Sources: 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension; 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults.

TOTUM•854, to reduce elevated blood pressure, a risk factor for cardiovascular diseases

TOTUM•854 is a unique patented combination of plant extracts, designed to reduce blood pressure in people with low to moderate elevated blood pressure, a risk factor for cardiovascular diseases.
TOTUM•854 could provide a new opportunity on a global market of more than one billion people, as no non-drug product has shown solid clinical evidence to date or received a health claim authorization relative to the reduction of blood pressure.

Phase II clinical study pending

A Phase II randomized, placebo-controlled, double-blind clinical study will include subjects with low to moderate elevated blood pressure.
Its primary endpoint will be the reduction of systolic blood pressure. The launch of the study is planned for the first half of 2021, and initial results are expected at the beginning of 2022.
The TOTUM•854 development program is ready to start Phase II clinical trials to obtain a health claim authorization for blood pressure reduction in Europe and North America.

Intellectual property

Valbiotis has adopted a global strategy to protect its intellectual property: patent applications have been filed for TOTUM•854 in 61 countries, including key markets: Europe, USA, Canada, China, Russia, Japan, Brazil and Australia.
Patents have already been issued in more than 40 countries, including in the United States, Europe (39 countries) and Russia, providing a very high level of protection.